O4‐04–06: Huperzine A for Alzheimer's Disease
Hongmei Wu,Jun Li,Rongxing Zhou,Guanjian Liu,Birong Dong
DOI: https://doi.org/10.1016/j.jalz.2008.05.532
2008-01-01
Abstract:Alzheimer's disease (AD) has become a major public health problem around the world due to its increasing prevalence, caregiver burden and high financial cost of care. The degeneration of acetylcholine-containing neurons in the basal forebrain has been implicated in the symptoms of AD. Cholinesterase inhibitors may block the degradation of acetylcholine, thus increasing the efficacy of the remaining cholinergic neurons. Huperzine A is a reversible inhibitor of acetyl cholinesterase. This systematic review is to assess the efficacy and safety of Huperzine A for AD. We performed a sensitive electronic search of multiple reference databases in the early 2006, including the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group which contains records from databases (MEDLINE, EMBASE, PsycINFO, CINAHL, SIGLE, ISTP, INSIDE, LILACS), CBM and AMED. We included all randomized clinical trials among patients with AD, which compared huperzine A with either placebo or routine treatment. Six trials including a total of 454 patients met our inclusion criteria. The methodological quality of most included trials was not high. It was shown that compared to placebo, Huperzine A had beneficial effects on the improvement of general cognitive function measured by MMSE (WMD 2.81; 95%CI 1.87 to 3.76) and ADAS-Cog (WMD 2.51; 95% CI 1.74 to 3.28), global clinical assessment measured by CIBIC-plus (OR 4.32,95%CI 2.37 to7.90), behavioral disturbance measured by ADAS-non Cog (WMD -1.52, 95%CI-2.39 to -0.65), and functional performance measured by ADL (WMD = -7.17; 95%CI -9.13 to -5.22). No data were available on all-cause mortality, quality of life and caregiver burden. The adverse events of Huperzine A were mild and there were no significant differences between Huperzine A groups and control groups. Huperzine A seems to have some beneficial effects on improvement of general cognitive function, global clinical status, behavioral disturbance and functional performance, with no obvious serious adverse events for patients with AD, but the small trials with limited numbers of patients and their low methodological quality has resulted in cautious assessment of the results. Rigorous design, randomized, multi-centre, large-sample trials of Huperzine A for AD are needed to further assess the effects.